Real World Use of Tocilizumab Biosimilar studY
- Conditions
- Rheumatoid Arthritis
- First Posted Date
- 2024-02-08
- Last Posted Date
- 2024-04-23
- Lead Sponsor
- Fresenius Kabi SwissBioSim GmbH
- Target Recruit Count
- 600
- Registration Number
- NCT06247722
- Locations
- 🇩🇪
Rheumatologische Schwerpunktpraxis Berlin, Berlin, Germany
🇩🇪Rheumapraxis Dr. Liebhaber Halle, Halle, Germany
🇩🇪Facharztpraxis für Innere Medizin Ludwigsfelde, Ludwigsfelde, Germany
A Study to Evaluate the Efficacy, Pharmacodynamics, Safety, and Immunogenicity of FKS518 in Postmenopausal Women With Osteoporosis
- Conditions
- Postmenopausal Osteoporosis
- Interventions
- Drug: US-licensed Prolia (Amgen)
- First Posted Date
- 2021-06-22
- Last Posted Date
- 2025-02-27
- Lead Sponsor
- Fresenius Kabi SwissBioSim GmbH
- Target Recruit Count
- 553
- Registration Number
- NCT04934072
- Locations
- 🇵🇱
Osteo-Medic sc dr diabetolog Katarzyna Wasilewska, Białystok, Podlaskie, Poland
🇵🇱Centrum Kliniczno Badawcze J Brzezicki B Górnikiewicz Brzezicka Lekarze, Elbląg, Warminsko-Mazurskie, Poland
🇵🇱Ambulatorium Sp z o.o. - Elblag, Elbląg, Zulawy, Poland
MSB11456 in Participants With Moderately to Severely Active Rheumatoid Arthritis
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2020-08-13
- Last Posted Date
- 2023-06-27
- Lead Sponsor
- Fresenius Kabi SwissBioSim GmbH
- Target Recruit Count
- 604
- Registration Number
- NCT04512001
- Locations
- 🇧🇬
Medical Center Hipokrat 2000 OOD, Haskovo, Khaskovo, Bulgaria
🇧🇬MHAT "Lyulin" EAD, Sofia, Sofiya, Bulgaria
🇧🇬Military Medical Academy - Sofia, Sofia, Sofiya, Bulgaria
Comparison of PK and Tolerability of MSB11022 Administered by AI or PFS
- Conditions
- Crohn DiseaseAnkylosing SpondylitisUlcerative ColitisPediatric Crohns DiseaseNon-infectious UveitisRheumatoid ArthritisPolyarticular Juvenile Idiopathic ArthritisPsoriatic ArthritisHidradenitis SuppurativaPlaque Psoriasis
- Interventions
- Drug: 40 mg MSB11022
- First Posted Date
- 2019-07-12
- Last Posted Date
- 2020-03-25
- Lead Sponsor
- Fresenius Kabi SwissBioSim GmbH
- Target Recruit Count
- 216
- Registration Number
- NCT04018599
- Locations
- 🇺🇸
PRA Health Sciences (PRA) - Early Development Services (EDS), Lenexa, Kansas, United States
🇺🇸PRA-EDS, Salt Lake City, Utah, United States
Pharmacokinetics/Pharmacodynamics (PK/PD) Equivalence Study of MSB11456
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2017-09-14
- Last Posted Date
- 2020-02-12
- Lead Sponsor
- Fresenius Kabi SwissBioSim GmbH
- Target Recruit Count
- 696
- Registration Number
- NCT03282851
- Locations
- 🇳🇿
Research site, Christchurch, New Zealand
Safety and Immunogenicity of MSB11455 in Healthy Participants
- First Posted Date
- 2017-08-16
- Last Posted Date
- 2019-07-02
- Lead Sponsor
- Fresenius Kabi SwissBioSim GmbH
- Target Recruit Count
- 336
- Registration Number
- NCT03251339
- Locations
- 🇳🇿
Auckland Clinical Studies Ltd, Auckland, New Zealand
🇳🇿Christchurch Clinical Studies Trust, Christchurch, New Zealand
Pharmacokinetic/Pharmacodynamic Equivalence of MSB11455 in Healthy Subjects
- First Posted Date
- 2017-08-16
- Last Posted Date
- 2019-07-02
- Lead Sponsor
- Fresenius Kabi SwissBioSim GmbH
- Target Recruit Count
- 294
- Registration Number
- NCT03251248
- Locations
- 🇦🇺
Nucleus Network, Melbourne, Victoria, Australia
🇦🇺Q-Pharm Pty Ltd, Herston, Australia
MSB11022 in Moderate to Severe Rheumatoid Arthritis
- Conditions
- Moderate to Severe Rheumatoid Arthritis
- Interventions
- Drug: EU-Humira
- First Posted Date
- 2017-02-14
- Last Posted Date
- 2019-12-20
- Lead Sponsor
- Fresenius Kabi SwissBioSim GmbH
- Target Recruit Count
- 288
- Registration Number
- NCT03052322
- Locations
- 🇧🇬
MHAT "Trimontium", OOD, Plovdiv, Bulgaria
🇧🇬MHAT-Plovdiv AD, Plovdiv, Bulgaria
🇧🇬UMHAT "Kaspela", EOOD, Plovdiv, Bulgaria
MSB11022 in Healthy Subjects
- Conditions
- Healthy Subjects
- Interventions
- First Posted Date
- 2017-01-09
- Last Posted Date
- 2019-07-01
- Lead Sponsor
- Fresenius Kabi SwissBioSim GmbH
- Target Recruit Count
- 237
- Registration Number
- NCT03014947
MSB11022 in Moderate to Severe Chronic Plaque Psoriasis
- Conditions
- Moderate to Severe Plaque PsoriasisPlaque Type PsoriasisPsoriasis
- Interventions
- First Posted Date
- 2016-01-21
- Last Posted Date
- 2023-12-27
- Lead Sponsor
- Fresenius Kabi SwissBioSim GmbH
- Target Recruit Count
- 443
- Registration Number
- NCT02660580
- Locations
- 🇺🇸
San Luis Dermatology & Laser Clinic, Inc., San Luis Obispo, California, United States
🇺🇸Florida Academic Centers Research and Education, Coral Gables, Florida, United States
🇺🇸Palm Beach Research Center, West Palm Beach, Florida, United States